Latest Lung Updates from ASCO 2010

posted Jun 15 2010
We would like to thank Dr Charles Butts for the latest lung updates.

Clinical Activity of the Oral ALK Inhibitor, Crizotinib (PF-02341066), in Patients with ALK-positive Non-small Cell Lung Cancer

International multicenter randomized phase III study of 1^st line erlotibnib followed by 2^nd line cisplatin + gemcitabine vs. 1^st line cisplatin + gemcitabine followed by 2nd line erlotinib in advanced NSCLC. The TORCH trial